



ABLATION FRONTIERS ANNOUNCES CE MARK FOR NOVEL CARDIAC ABLATION CATHETERS

Regulatory Approval Clears Path Towards European Commercialization

Carlsbad, CA, December 19, 2006—Ablation Frontiers, Inc., developer and manufacturer of three-dimensional catheters for the treatment of atrial fibrillation (AF) announced today that it has received the CE Mark for its Cardiac Ablation System consisting of a portfolio of 3 catheters and a novel RF energy delivery system. CE Mark certification allows the company to initiate use of its system throughout the European Union and other International markets that recognize the CE mark.

Ablation Frontiers proprietary devices are used to treat tissue in the right and/or left atrium of the heart during an AF ablation procedure. Unlike traditional technologies used for this procedure, Ablation Frontiers Inc. has invented and developed a portfolio of custom catheters, for use with standard Fluoroscopy imaging, designed for the atrial anatomy along with a custom RF energy delivery system to tailor lesions for the individual needs of the patient. The Company's percutaneous cardiac catheters are inserted through a vein in the leg of the patient and advanced into the right and/or left atrium. Each of the catheters is designed to map and using radiofrequency energy, ablate specific target sites through either single selected or multiple channels simultaneously.

This results in a significant reduction of time required for the procedure and increased accuracy for the physician due to the stabilizing nature of the three-dimensional catheters. Traditional ablation can take up to 6 hours or greater. The Ablation Frontiers portfolio of catheters and RF energy system allows physicians to tailor the ablation therapy to suit the needs of each patient.

"It's truly exciting to be at the forefront of new technology to treat atrial fibrillation that is curative rather than palliative," stated Keegan Harper, CEO of Ablation Frontiers. "We are very pleased with the results of our European clinical trials and are looking forward to the launch of our technology into the European and key international markets",

Ablation procedures are used to treat cardiac arrhythmias, such as Atrial Fibrillation. AF is an uncontrollable, rapid heartbeat that can lead to serious complications like strokes or Heart Failure. Globally, in excess of 10 million people are afflicted with AF. During the Ablation procedure, a catheter is inserted into a specific area of the heart. Energy is directed through the catheter to small areas of the heart muscle that permit the abnormal heart rhythm. This energy "disconnects" the pathway of the abnormal rhythm.

The Cardiac Ablation Technology System provides a catheter-based solution to AF that is appropriate for most hospital facilities when performed by a cardiac electrophysiologist.

Ablation Frontiers is a privately held company that was founded in 2004.

For more information, visit the Ablation Frontiers web site at www.ablationfrontiers.com